Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug;35(4):815-828.
doi: 10.1007/s10557-020-07007-8.

CD38: A Potential Therapeutic Target in Cardiovascular Disease

Wanyun Zuo #  1 , Na Liu #  1 , Yunhong Zeng  2 , Yaozhong Liu  1 , Biao Li  1 , Keke Wu  1 , Yunbin Xiao  3 , Qiming Liu  4
Affiliations
Review

CD38: A Potential Therapeutic Target in Cardiovascular Disease

Wanyun Zuo et al. Cardiovasc Drugs Ther. 2021 Aug.

Abstract

Substantial research has demonstrated the association between cardiovascular disease and the dysregulation of intracellular calcium, ageing, reduction in nicotinamide adenine dinucleotide NAD+ content, and decrease in sirtuin activity. CD38, which comprises the soluble type, type II, and type III, is the main NADase in mammals. This molecule catalyses the production of cyclic adenosine diphosphate ribose (cADPR), nicotinic acid adenine dinucleotide phosphate (NAADP), and adenosine diphosphate ribose (ADPR), which stimulate the release of Ca2+, accompanied by NAD+ consumption and decreased sirtuin activity. Therefore, the relationship between cardiovascular disease and CD38 has been attracting increased attention. In this review, we summarize the structure, regulation, function, targeted drug development, and current research on CD38 in the cardiac context. More importantly, we provide original views about the as yet elusive mechanisms of CD38 action in certain cardiovascular disease models. Based on our review, we predict that CD38 may serve as a novel therapeutic target in cardiovascular disease in the future.

Keywords: CD38; Calcium regulation; Cardiovascular diseases; NAD +; Sirtuins; cADPR.

PubMed Disclaimer

References

    1. Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci U S A. 1980;77:1588–92. - PubMed - PMC
    1. Howard M, Grimaldi JC, Bazan JF, Lund FE, Santos-Argumedo L, Parkhouse RM, et al. Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science. 1993;262:1056–9. - PubMed
    1. Aarhus R, Graeff RM, Dickey DM, Walseth TF, Lee HC. ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. J Biol Chem. 1995;270:30327–33. - PubMed
    1. Aksoy P, White TA, Thompson M, Chini EN. Regulation of intracellular levels of NAD: a novel role for CD38. Biochem Biophys Res Commun. 2006;345:1386–92. - PubMed
    1. Koguma T, Takasawa S, Tohgo A, Karasawa T, Furuya Y, Yonekura H, et al. Cloning and characterization of cDNA encoding rat ADP-ribosyl cyclase / cyclic ADP-ribose hydrolase (homologue to human CD38) from islets of Langerhans. Biochimica et Biophysica Acta (BBA) - Mole Cell Res. 1994;1223:160–2.

Publication types

MeSH terms

LinkOut - more resources